Innate Pharma Company Profile (NASDAQ:IPHYF)

About Innate Pharma (NASDAQ:IPHYF)

Innate Pharma logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IPHYF
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $13.00
  • 200 Day Moving Avg: $13.09
  • 52 Week Range: $10.36 - $16.55
P/E:
  • Trailing P/E Ratio: 53.10
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $73.58 million
  • Price / Sales: N/A
  • Book Value: $1.79 per share
  • Price / Book: 7.65
Profitability:
  • EBIDTA: $12.13 million
Misc:
  • Average Volume: 705 shs.
 

Frequently Asked Questions for Innate Pharma (NASDAQ:IPHYF)

What is Innate Pharma's stock symbol?

Innate Pharma trades on the NASDAQ under the ticker symbol "IPHYF."

Who are some of Innate Pharma's key competitors?

How do I buy Innate Pharma stock?

Shares of Innate Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innate Pharma's stock price today?

One share of Innate Pharma stock can currently be purchased for approximately $13.70.


MarketBeat Community Rating for Innate Pharma (NASDAQ IPHYF)
Community Ranking:  1.9 out of 5 ()
Outperform Votes:  19 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  51
MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Innate Pharma (NASDAQ:IPHYF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Innate Pharma (NASDAQ:IPHYF)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/5/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 6/25/2015 forward)

Earnings

Earnings History for Innate Pharma (NASDAQ:IPHYF)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Innate Pharma (NASDAQ:IPHYF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Innate Pharma (NASDAQ:IPHYF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Innate Pharma (NASDAQ:IPHYF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Innate Pharma (NASDAQ:IPHYF)
Latest Headlines for Innate Pharma (NASDAQ:IPHYF)
Source:
DateHeadline
americanbankingnews.com logoZacks: Innate Pharma (IPHYF) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 21 at 8:04 AM
seekingalpha.com logoInnate Pharma (IPHYF) Acquires First-In-Class Anti-C5AR Antibody - Slideshow
seekingalpha.com - June 16 at 6:12 AM
finance.yahoo.com logoINNATE PHARMA : Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102
finance.yahoo.com - June 15 at 6:29 AM
americanbankingnews.com logo Innate Pharma (IPHYF) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 6 at 8:17 PM
seekingalpha.com logoNovo Nordisk out-licenses I-O candidate to Innate Pharma for up to €410M
seekingalpha.com - June 2 at 7:23 PM
finance.yahoo.com logoInnate Pharma acquires anti-C5aR, a first-in-class clinical-stage antibody, from Novo Nordisk A/S
finance.yahoo.com - June 2 at 7:23 PM
finance.yahoo.com logoInnate Pharma to hold its Annual General Meeting of shareholders on June 23, 2017
finance.yahoo.com - May 23 at 11:13 AM
finance.yahoo.com logoINNATE PHARMA : IPH4102: Completion of the dose escalation part of the phase I trial - Data to be presented at ICML in June 2017 in Lugano
finance.yahoo.com - May 22 at 10:45 AM
americanbankingnews.com logoZacks: Innate Pharma (IPHYF) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - May 19 at 10:04 AM
americanbankingnews.com logoZacks Investment Research Upgrades Innate Pharma (IPHYF) to "Hold"
www.americanbankingnews.com - May 10 at 12:50 AM
finance.yahoo.com logoNUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT MAY 5, 2017
finance.yahoo.com - May 9 at 12:21 PM
americanbankingnews.com logoZacks: Innate Pharma (IPHYF) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 3 at 10:04 AM
americanbankingnews.com logoZacks: Innate Pharma (IPHYF) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 18 at 8:38 AM
americanbankingnews.com logoInnate Pharma (IPHYF) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 13 at 12:40 AM
americanbankingnews.com logoInnate Pharma (IPHYF) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 8 at 3:35 PM
finance.yahoo.com logoINNATE PHARMA reports its consolidated financial results for the year ended December 31, 2016
finance.yahoo.com - April 7 at 10:30 AM
finance.yahoo.com logoINNATE PHARMA: Expansion of Phase I/II trial evaluating lirilumab in combination with Opdivo
finance.yahoo.com - April 7 at 10:30 AM
finance.yahoo.com logoINNATE PHARMA : 2016 reference document made available (in french)
finance.yahoo.com - April 7 at 10:30 AM
finance.yahoo.com logoINNATE PHARMA : Number of shares and voting rights of Innate Pharma as at April 4, 2017
finance.yahoo.com - April 7 at 10:30 AM
americanbankingnews.com logo Innate Pharma (IPHYF) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - April 6 at 8:04 AM
americanbankingnews.com logoInnate Pharma (IPHYF) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 5 at 7:36 AM
americanbankingnews.com logoInnate Pharma (IPHYF) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 24 at 12:28 PM
seekingalpha.com logoInnate Pharma's (IPHYF) CEO Mondher Mahjoubi on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 7 at 10:44 PM
seekingalpha.com logoBristol-Myers Squibb And Innate Pharma: Innovation Is Never A Single Event
seekingalpha.com - March 6 at 5:30 PM
seekingalpha.com logoEffikir Fail Sets Up An Innate Dream Scenario
seekingalpha.com - February 7 at 7:16 PM
seekingalpha.com logoBristol-Myers' lirilumab flunks mid-stage study in leukemia
seekingalpha.com - February 6 at 6:02 PM
thestreet.com logoInnate Pharma Pops as It Names AstraZeneca's Oncology Head as Chairman
www.thestreet.com - February 4 at 5:59 PM
finance.yahoo.com logo10:23 pm Innate Pharma reported Phase I study protocol investigating IPH4102 in cutaneous T-Cell lymphomas - continues on track in EU and US centers
finance.yahoo.com - June 5 at 10:23 PM
finance.yahoo.com logoShould Innate Pharma (IPHYF) Be On Your Radar Now?
finance.yahoo.com - October 9 at 8:45 AM
finance.yahoo.com logoAstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog
finance.yahoo.com - April 24 at 5:43 PM

Social

Chart

Innate Pharma (IPHYF) Chart for Sunday, June, 25, 2017

This page was last updated on 6/25/2017 by MarketBeat.com Staff